Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CORCEPT THERAPEUTICS INC reported revenue of $761M, up 12.8% year over year. Operating margin was 5.9% and net margin 13.1%, on a free-cash-flow margin of 18.6% with capital expenditure at 0.0% of revenue. Every figure is computed directly from CORT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $761M | 5.9% | 13.1% |
| FY2024 | $675M | 20.3% | 20.9% |
| FY2023 | $482M | 22.2% | 22.0% |
| FY2022 | $402M | 28.0% | 25.2% |
| FY2021 | $366M | 34.0% | 30.7% |
How does CORT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.